Skip to main content

22-11-2011 | Diabetes | Article

Serum chemokine CXCL5 a marker for subclinical atherosclerosis in diabetes


Free abstract

MedWire News: Serum chemokine CXC ligand 5 (CXCL5) is associated with carotid artery intima-media thickness (IMT) in patients with Type 2 diabetes, researchers report.

"Our findings suggest that serum CXCL5 may play an important role in the increased cardiovascular (CV) risk observed in this disease," they write in the journal Clinical Endocrinology.

The researchers say their previous work has revealed a strong association between elevated CXCL5 levels and hypercholesterolemia in middle-aged and elderly Chinese individuals, independently of obesity, inflammation, adipokines, and other risk factors. They also observed that the incidence of self-reported CV disease increased with CXCL5 quartiles in both males and females.

In the current study, led by Zhen Yang (Tongji University, Shanghai, China), the team examined the association between CXCL5 levels and common carotid IMT in 730 diabetes patients (over 30 years of age) in a cross-sectional community-based study performed in Shanghai.

The participants' biochemical, inflammatory and anthropometric parameters were also measured.

The study revealed that serum CXCL5 correlated with carotid artery IMT, at a correlation coefficient of 0.12, after adjustment for age and gender.

This correlation remained statistically significant after further adjustment for serum C-reactive protein (CRP) and glycated hemoglobin (HbA1c) level, at a correlation coefficient of 0.11.

"This association is independent of inflammation and glucose control, as CRP is a serum marker for low-grade inflammation and HbA1c reflects the average glucose control," say Yang et al. "Hence our study shows that serum CXCL5 is an independent determinant of carotid artery IMT in patients with Type 2 diabetes."

The researchers say the mechanism underlying this association is still to be explored.

"Measurement of serum CXCL5 could be useful for CV risk stratification in Type 2 diabetes," concludes the team.

MedWire ( is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010

By Sally Robertson

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits